Recent research from the Alzheimer’s Association suggests a connection between biological age, assessed through blood tests, and the risk of dementia. This study, conducted in the UK, used data from the UK Biobank, involving over 223,000 participants. Researchers focused on blood metabolites, small molecules related to fat processing, inflammation, and energy use.
Research Findings
Among the participants, nearly 4,000 developed dementia over the study period. Researchers used a measure called MileAge delta, calculated as metabolite-predicted age minus actual age. A higher MileAge delta indicates an older blood profile, while a lower delta indicates a younger profile. Participants with a higher MileAge delta and an increased genetic risk for dementia faced a tenfold higher risk of all-cause dementia.
Results showed a strong link between a higher MileAge delta and various forms of dementia, particularly vascular dementia. Those carrying the APOE gene, associated with Alzheimer’s, and exhibiting a higher MileAge delta, had a tenfold risk increase.
Implications of the Study
Study co-author Dr. Julian Mutz from King’s College London highlighted the significant risk associated with combining genetic predispositions and biological aging. He emphasized the importance of understanding other risk factors beyond genetics.
Mutz noted that biological aging measured through metabolites could be modified by lifestyle or clinical interventions. Managing cardiovascular risks, maintaining physical activity, and monitoring mental health might slow biological aging and reduce dementia risk.
Additional Insights
Fox News senior medical analyst Dr. Marc Siegel commented on the research, emphasizing the distinction between healthspan and lifespan, as well as the influential role of the APOE gene. He pointed out the increased risk of vascular dementia when combined with chronic illnesses like heart disease and obesity.
Study Limitations and Considerations
Researchers acknowledged limitations within the study. Being observational, it indicated only an association rather than causation between older biological age and increased dementia risk. The UK Biobank participants were not fully representative of the general population, being mostly healthier and of European descent. Moreover, the study relied on a single blood measurement, limiting the ability to observe changes over time.
The MileAge biomarker requires further validation for clinical use. The study’s findings underscore the potential for delaying or preventing dementia through modification of risk factors, including biological aging.
Angelica Stabile reported this for Fox News Digital.